vs
Side-by-side financial comparison of Root, Inc. (ROOT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $397.0M, roughly 1.6× Root, Inc.). On growth, Root, Inc. posted the faster year-over-year revenue change (21.5% vs 4.8%). Over the past eight quarters, Root, Inc.'s revenue compounded faster (24.8% CAGR vs 4.6%).
Root Insurance Company is an online car insurance company operating in the United States.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ROOT vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $397.0M | $622.0M |
| Net Profit | — | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 2.6% | 62.4% |
| Net Margin | — | 34.4% |
| Revenue YoY | 21.5% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | $0.35 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $397.0M | $622.0M | ||
| Q3 25 | $387.8M | $609.3M | ||
| Q2 25 | $382.9M | $578.7M | ||
| Q1 25 | $349.4M | $568.2M | ||
| Q4 24 | $326.7M | $593.6M | ||
| Q3 24 | $305.7M | $564.7M | ||
| Q2 24 | $289.2M | $537.3M | ||
| Q1 24 | $254.9M | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | $-5.4M | $288.2M | ||
| Q2 25 | $22.0M | $30.2M | ||
| Q1 25 | $18.4M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $22.8M | $544.0M | ||
| Q2 24 | $-7.8M | $102.0M | ||
| Q1 24 | $-6.2M | $4.8M |
| Q4 25 | 2.6% | 62.4% | ||
| Q3 25 | 0.1% | 70.1% | ||
| Q2 25 | 7.1% | 36.3% | ||
| Q1 25 | 6.8% | 94.0% | ||
| Q4 24 | 10.7% | 60.9% | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 1.3% | 50.2% | ||
| Q1 24 | 2.1% | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | -1.4% | 47.3% | ||
| Q2 25 | 5.7% | 5.2% | ||
| Q1 25 | 5.3% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 7.5% | 96.3% | ||
| Q2 24 | -2.7% | 19.0% | ||
| Q1 24 | -2.4% | 0.8% |
| Q4 25 | $0.35 | $0.49 | ||
| Q3 25 | $-0.35 | $0.67 | ||
| Q2 25 | $1.29 | $0.07 | ||
| Q1 25 | $1.07 | $0.55 | ||
| Q4 24 | $1.42 | $0.46 | ||
| Q3 24 | $1.35 | $1.21 | ||
| Q2 24 | $-0.52 | $0.23 | ||
| Q1 24 | $-0.42 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $669.3M | $618.7M |
| Total DebtLower is stronger | $200.3M | $9.0B |
| Stockholders' EquityBook value | $284.3M | $9.7B |
| Total Assets | $1.7B | $19.6B |
| Debt / EquityLower = less leverage | 0.70× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $669.3M | $618.7M | ||
| Q3 25 | $653.3M | $938.9M | ||
| Q2 25 | $641.4M | $631.9M | ||
| Q1 25 | $609.4M | $1.1B | ||
| Q4 24 | $599.3M | $929.0M | ||
| Q3 24 | $674.8M | $950.1M | ||
| Q2 24 | $667.2M | $1.8B | ||
| Q1 24 | $640.5M | $843.0M |
| Q4 25 | $200.3M | $9.0B | ||
| Q3 25 | $200.4M | $8.9B | ||
| Q2 25 | $200.1M | $8.0B | ||
| Q1 25 | $200.0M | $7.6B | ||
| Q4 24 | $200.1M | $7.6B | ||
| Q3 24 | $300.9M | $7.6B | ||
| Q2 24 | $300.1M | $7.6B | ||
| Q1 24 | $299.3M | $6.1B |
| Q4 25 | $284.3M | $9.7B | ||
| Q3 25 | $265.0M | $9.6B | ||
| Q2 25 | $244.5M | $9.5B | ||
| Q1 25 | $228.7M | $9.8B | ||
| Q4 24 | $203.7M | $10.3B | ||
| Q3 24 | $181.9M | $10.3B | ||
| Q2 24 | $151.3M | $9.8B | ||
| Q1 24 | $165.7M | $9.9B |
| Q4 25 | $1.7B | $19.6B | ||
| Q3 25 | $1.6B | $19.3B | ||
| Q2 25 | $1.6B | $18.3B | ||
| Q1 25 | $1.6B | $17.6B | ||
| Q4 24 | $1.5B | $18.2B | ||
| Q3 24 | $1.6B | $18.0B | ||
| Q2 24 | $1.5B | $17.7B | ||
| Q1 24 | $1.4B | $16.1B |
| Q4 25 | 0.70× | 0.92× | ||
| Q3 25 | 0.76× | 0.93× | ||
| Q2 25 | 0.82× | 0.84× | ||
| Q1 25 | 0.87× | 0.78× | ||
| Q4 24 | 0.98× | 0.74× | ||
| Q3 24 | 1.65× | 0.74× | ||
| Q2 24 | 1.98× | 0.78× | ||
| Q1 24 | 1.81× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.5M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.5M | $827.1M | ||
| Q3 25 | $57.6M | $702.6M | ||
| Q2 25 | $52.0M | $364.0M | ||
| Q1 25 | $26.8M | $596.1M | ||
| Q4 24 | $195.7M | $742.5M | ||
| Q3 24 | $49.4M | $703.6M | ||
| Q2 24 | $62.6M | $658.2M | ||
| Q1 24 | $14.5M | $664.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $195.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | $14.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 5.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 2.36× | 12.06× | ||
| Q1 25 | 1.46× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.17× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ROOT
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
